282 related articles for article (PubMed ID: 22133876)
1. Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR.
Schoppy DW; Ragland RL; Gilad O; Shastri N; Peters AA; Murga M; Fernandez-Capetillo O; Diehl JA; Brown EJ
J Clin Invest; 2012 Jan; 122(1):241-52. PubMed ID: 22133876
[TBL] [Abstract][Full Text] [Related]
2. Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner.
Gilad O; Nabet BY; Ragland RL; Schoppy DW; Smith KD; Durham AC; Brown EJ
Cancer Res; 2010 Dec; 70(23):9693-702. PubMed ID: 21098704
[TBL] [Abstract][Full Text] [Related]
3. Protection from UV-induced skin carcinogenesis by genetic inhibition of the ataxia telangiectasia and Rad3-related (ATR) kinase.
Kawasumi M; Lemos B; Bradner JE; Thibodeau R; Kim YS; Schmidt M; Higgins E; Koo SW; Angle-Zahn A; Chen A; Levine D; Nguyen L; Heffernan TP; Longo I; Mandinova A; Lu YP; Conney AH; Nghiem P
Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13716-21. PubMed ID: 21844338
[TBL] [Abstract][Full Text] [Related]
4. Mice hypomorphic for Atr have increased DNA damage and abnormal checkpoint response.
Ragland RL; Arlt MF; Hughes ED; Saunders TL; Glover TW
Mamm Genome; 2009 Jun; 20(6):375-85. PubMed ID: 19504344
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link-generating agents in vitro and in vivo.
Wang HC; Lee AY; Chou WC; Wu CC; Tseng CN; Liu KY; Lin WL; Chang FR; Chuang DW; Hunyadi A; Wu YC
Mol Cancer Ther; 2012 Jul; 11(7):1443-53. PubMed ID: 22532598
[TBL] [Abstract][Full Text] [Related]
6. ATR mediates cisplatin resistance in a p53 genotype-specific manner.
Sangster-Guity N; Conrad BH; Papadopoulos N; Bunz F
Oncogene; 2011 Jun; 30(22):2526-33. PubMed ID: 21258400
[TBL] [Abstract][Full Text] [Related]
7. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
8. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression.
Armata HL; Garlick DS; Sluss HK
Cancer Res; 2007 Dec; 67(24):11696-703. PubMed ID: 18089799
[TBL] [Abstract][Full Text] [Related]
9. p53: guardian of the genome and policeman of the oncogenes.
Efeyan A; Serrano M
Cell Cycle; 2007 May; 6(9):1006-10. PubMed ID: 17457049
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the ataxia telangiectasia and rad3-related-checkpoint kinase 1 DNA damage response axis in colon cancers.
Lewis KA; Bakkum-Gamez J; Loewen R; French AJ; Thibodeau SN; Cliby WA
Genes Chromosomes Cancer; 2007 Dec; 46(12):1061-8. PubMed ID: 17879369
[TBL] [Abstract][Full Text] [Related]
11. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
Peasland A; Wang LZ; Rowling E; Kyle S; Chen T; Hopkins A; Cliby WA; Sarkaria J; Beale G; Edmondson RJ; Curtin NJ
Br J Cancer; 2011 Jul; 105(3):372-81. PubMed ID: 21730979
[TBL] [Abstract][Full Text] [Related]
12. RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells.
Mukhopadhyay UK; Senderowicz AM; Ferbeyre G
Cancer Res; 2005 Apr; 65(7):2872-81. PubMed ID: 15805289
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
Gallmeier E; Hermann PC; Mueller MT; Machado JG; Ziesch A; De Toni EN; Palagyi A; Eisen C; Ellwart JW; Rivera J; Rubio-Viqueira B; Hidalgo M; Bunz F; Göke B; Heeschen C
Stem Cells; 2011 Mar; 29(3):418-29. PubMed ID: 21308861
[TBL] [Abstract][Full Text] [Related]
14. Disease severity in a mouse model of ataxia telangiectasia is modulated by the DNA damage checkpoint gene Hus1.
Balmus G; Zhu M; Mukherjee S; Lyndaker AM; Hume KR; Lee J; Riccio ML; Reeves AP; Sutter NB; Noden DM; Peters RM; Weiss RS
Hum Mol Genet; 2012 Aug; 21(15):3408-20. PubMed ID: 22575700
[TBL] [Abstract][Full Text] [Related]
15. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations.
Toledo LI; Murga M; Zur R; Soria R; Rodriguez A; Martinez S; Oyarzabal J; Pastor J; Bischoff JR; Fernandez-Capetillo O
Nat Struct Mol Biol; 2011 Jun; 18(6):721-7. PubMed ID: 21552262
[TBL] [Abstract][Full Text] [Related]
16. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
17. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
18. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence.
Mallette FA; Gaumont-Leclerc MF; Ferbeyre G
Genes Dev; 2007 Jan; 21(1):43-8. PubMed ID: 17210786
[TBL] [Abstract][Full Text] [Related]
19. Germline mutation in ATR in autosomal- dominant oropharyngeal cancer syndrome.
Tanaka A; Weinel S; Nagy N; O'Driscoll M; Lai-Cheong JE; Kulp-Shorten CL; Knable A; Carpenter G; Fisher SA; Hiragun M; Yanase Y; Hide M; Callen J; McGrath JA
Am J Hum Genet; 2012 Mar; 90(3):511-7. PubMed ID: 22341969
[TBL] [Abstract][Full Text] [Related]
20. Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability.
Li J; Sejas DP; Burma S; Chen DJ; Pang Q
Carcinogenesis; 2007 Jun; 28(6):1163-70. PubMed ID: 17277230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
